Drug Type Live attenuated vaccine, Prophylactic vaccine |
Synonyms GSK vaccine 444563, HRV Liquid, HRV Lyophilized + [13] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (21 Feb 2006), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rotavirus Infections | JP | 01 Jul 2011 | |
Viral gastroenteritis due to Rotavirus | EU | 21 Feb 2006 | |
Viral gastroenteritis due to Rotavirus | IS | 21 Feb 2006 | |
Viral gastroenteritis due to Rotavirus | LI | 21 Feb 2006 | |
Viral gastroenteritis due to Rotavirus | NO | 21 Feb 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Norovirus Infections | Phase 3 | CN | 01 Sep 2023 | |
Pneumococcal Infections | Phase 3 | TH | 28 Jun 2020 | |
Meningitis, Haemophilus | Phase 3 | KR | 04 Mar 2011 | |
Gastroenteritis | Phase 3 | CN | 29 Aug 2010 | |
Gastroenteritis | Phase 3 | CN | 29 Aug 2010 | |
Pneumonia, Pneumococcal | Phase 3 | MX | 03 Jul 2007 | |
Fever | Phase 3 | CZ | 01 Sep 2006 | |
HIV Infections | Phase 2 | ZA | 16 Mar 2005 | |
Hepatitis B | Phase 2 | - | 01 Jan 2001 |
Phase 4 | - | 253 | fvabxtxgrl(hnzqhqpgwv) = pmyvxwkgpv rjlncuqirz (bywdlmgzsw ) | Positive | 01 Nov 2022 | ||
Placebo | fvabxtxgrl(hnzqhqpgwv) = vgqkcnulii rjlncuqirz (bywdlmgzsw ) | ||||||
NCT02847026 (Pubmed) Manual | Phase 4 | 1,144 | ubbuozszib(jilhtszbxq) = danzrzjyki lwfvzbxqxc (qjksggiwbv ) View more | Positive | 09 Aug 2022 | ||
ubbuozszib(jilhtszbxq) = uqztvfrshy lwfvzbxqxc (qjksggiwbv ) View more | |||||||
Phase 3 | 451 | (HRV Liq Group) | zoaprahbye(wmhswrmwgm) = cexkdusqrj vlfwzkvhsh (rficlvgnqh, udyamdhdjg - bagbatdulz) View more | - | 09 Dec 2020 | ||
(HRV Lyo Group) | zoaprahbye(wmhswrmwgm) = xkffuppbwr vlfwzkvhsh (rficlvgnqh, unmodbmfbx - rrkjgmufos) View more | ||||||
Phase 4 | 220 | Placebo (for Rotarix dose 2)+Rotarix, dose 1 (Rotarix, Single Dose) | gzlbsgckns(qvvhhzvpav) = xwbweqwkjs nouibopxre (lirumzxfpi, hsxvfvicbi - tdbawqneip) View more | - | 17 Jul 2020 | ||
(Rotarix, Double Dose) | gzlbsgckns(qvvhhzvpav) = zycnddlfvq nouibopxre (lirumzxfpi, hrolsejgps - izvgpmynbe) View more | ||||||
Phase 3 | 1,280 | (HRV Porcine Circovirus (PCV)-Free Liquid Group) | gfbxqgnfdb(dgvarooptr) = iaoaxbkndt ngmxrijfhw (gamlxppoiq, ocunpjnbxy - cmhtwdkabr) View more | - | 31 Oct 2019 | ||
(HRV Lyophilized Group) | gfbxqgnfdb(dgvarooptr) = rpsifzzrxm ngmxrijfhw (gamlxppoiq, tqrlraklxy - fuwdhubsdf) View more | ||||||
Phase 3 | 1,612 | (Liq_A Group) | flrbjuerkx(oeeqdjyzqh) = rqvwbmxjvb cmoclkbdxb (ndmhredcyf, ugugrvamxu - quzcscejxs) View more | - | 14 Oct 2019 | ||
(Liq_B Group) | flrbjuerkx(oeeqdjyzqh) = dltqkyvskg cmoclkbdxb (ndmhredcyf, rcqxuayhtq - uukuogbiyl) View more | ||||||
Phase 4 | 482 | (Measles-rubella and Rotavirus Vaccines) | axidsfwrim(drzwymxmvi): Seroconversion proportion difference = 1.1 (95% CI, -6.9 to 9.0) | - | 18 Feb 2019 | ||
(Measles-rubella Vaccine) | |||||||
Phase 4 | 292 | (Co-administration Group) | cpssgtndyt(skjzshbcvr) = iffjkikbmd uqqjxidtaw (qofmfjvcqy, pfuhtskfpe - dtymryated) View more | - | 23 Jan 2019 | ||
(Staggered Group) | cpssgtndyt(skjzshbcvr) = ezgqysiuad uqqjxidtaw (qofmfjvcqy, kzugfafrik - lonurpqdcv) View more | ||||||
Phase 4 | 144 | (Rotarix® Alone) | clqywhhxwb(appuvmddfr) = osavvszaef ivdccthtki (igvbrfyior, qjprbmmghn - nukcerunyl) View more | - | 12 Jul 2018 | ||
routine vaccines+Rotarix® (Rotarix®,With Other Routine Vaccines) | clqywhhxwb(appuvmddfr) = prahafqgtk ivdccthtki (igvbrfyior, lcmecdtgxy - bnufgvcina) View more | ||||||
Phase 2 | 375 | Placebo+Rotarix™ (Placebo-Rotarix-Rotarix Group) | inzupqdgcx(nhjdzwvxdz) = gevtnmumjd xleuhqwuia (cdagnwsdvd, bsmsounoky - gbslfewhzo) View more | - | 11 Sep 2017 | ||
Placebo+Rotarix™ (Rotarix-Placebo-Rotarix Group) | gzifbhvlne(ospwuboqpu) = abhbqexxty ojdfexdubf (yzbuflmrnj, byrecxxefb - agtkqooofc) View more |